Gene therapy research firm catalyst has been served with a class action lawsuit in Delaware by attorneys who defended the company ’s acquisition by Intrexon , citing a lack of advantages and an inaccurate SEC registration statement .
Gene therapy research firm GenVec has been served with a class action lawsuit in Delaware by shareholders who oppose the company’s acquisition by Intrexon, citing a lack of advantages and an inaccurate SEC registration statement.